Compare MSN & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSN | BGLC |
|---|---|---|
| Founded | 1948 | 2017 |
| Country | United States | Malaysia |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 10.2M |
| IPO Year | 1994 | N/A |
| Metric | MSN | BGLC |
|---|---|---|
| Price | $0.43 | $4.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 80.3K | ★ 310.3K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $8,739,000.00 | ★ $9,465,006.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2.21 |
| 52 Week Low | $0.28 | $2.01 |
| 52 Week High | $0.85 | $15.60 |
| Indicator | MSN | BGLC |
|---|---|---|
| Relative Strength Index (RSI) | 46.66 | 40.78 |
| Support Level | $0.41 | $4.11 |
| Resistance Level | $0.44 | $4.60 |
| Average True Range (ATR) | 0.03 | 0.27 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 66.11 | 31.92 |
Emerson Radio Corp operates in the consumer electronics industry. The company designs, sources, imports, and markets a variety of houseware and consumer electronic products, and licenses the Emerson trademark domestically and internationally. The products offered by the company are televisions, digital versatile disc players and video cassette recorders, audio accessories, microwave ovens, home theatres, high-end audio products, office products, mobile stereo, and wireless products.
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.